Pharmacy & Acute Care University
Pharmacy & Acute Care University
Back to Course

PACULit Literature Updates September 2025: Oncology

0% Complete
0/0 Steps
  1. Immune mediated adverse events in the randomized phase 3 TOPAZ 1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer
    1 Topic
    |
    1 Quiz
  2. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma DREAMM7 updated overall survival analysis from a global randomised open label phase 3 trial
    1 Topic
    |
    1 Quiz
  3. PACULit Daily Literature Update: Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals An analysis using the Premier Healthcare Database
    1 Topic
    |
    1 Quiz
  4. PACULit Daily Literature Update: Effects of BojungikkiTang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors a randomized pilot study
    1 Topic
    |
    1 Quiz
  5. PACULit Daily Literature Update: Long acting lipegfilgrastim and antimicrobials as vigorous primary prophylaxis in bendamustine treated patients with indolent B cell non Hodgkin lymphoma a multicentric real life experience
    1 Topic
    |
    1 Quiz
  6. First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC a single-arm phase II study
    1 Topic
    |
    1 Quiz
  7. Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma
    1 Topic
    |
    1 Quiz
  8. Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer
    1 Topic
    |
    1 Quiz
  9. Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
    1 Topic
    |
    1 Quiz
  10. Phase I II clinical trial on the safety and preliminary efficacy of donor derived anti leukemia cytotoxic T lymphocytes for the prevention of leukemia relapse in children given haploidentical hematopoietic stem cell transplantation study rational and design
    1 Topic
    |
    1 Quiz
  11. Brentuximab vedotin plus chemotherapy for the treatment of frontline systemic anaplastic large cell lymphoma subgroup analysis of the ECHELON2 study at 5 years followup
    1 Topic
    |
    1 Quiz
  12. Effectiveness and Safety of Immunotherapy for Hepatocellular Carcinoma in Clinical Practice A Brazilian Multicenter Study
    1 Topic
    |
    1 Quiz
  13. Talquetamab improves patient reported symptoms and health related quality of life in relapsed or refractory multiple myeloma Results from the phase 12 MonumenTAL1 study
    1 Topic
    |
    1 Quiz
  14. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
    1 Topic
    |
    1 Quiz
  15. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non Small Cell Lung Cancer Update From the COAST Randomized Clinical Trial
    1 Topic
    |
    1 Quiz
  16. Real world patient profile and step up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals An analysis using the Premier Healthcare Database
    1 Topic
    |
    1 Quiz
  17. Virtual reality for outpatient management of cancer pain a pilot dosing study
    1 Topic
    |
    1 Quiz
  18. Brentuximab vedotin plus chemotherapy for the treatment of frontline systemic anaplastic large cell lymphoma
    1 Topic
    |
    1 Quiz
  19. Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors should we treat beyond two years
    1 Topic
    |
    1 Quiz
  20. Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Nivolumab
    1 Topic
    |
    1 Quiz
  21. ACPE Required Forms: PACULit Literature Updates September 2025: Oncology
    3 Topics

Quizzes

Participants 440

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson Progress
0% Complete
PACULit Logo

Daily Literature Update

Virtual reality for outpatient management of cancer pain a pilot dosing study

Groninger H, Violanti D, McPherson ML, Hopkins K, Carr AL, Hurtado M, et al. Support Care Cancer. 2025 Jul 14;33(8):690. PMID: 40653577.

Introduction

This pilot study evaluates virtual reality (VR) as a nonpharmacological option for outpatient chronic cancer pain management, exploring analgesic benefits and optimal dosing strategies over 3 weeks.

Study Type: Pilot dosing study

Population: 33 adults with chronic cancer pain (mean age 55, 73% women, 91% African American)

Intervention: Meta Quest 2 VR headset use: week 1 daily 10 min, week 2 twice daily 10 min, week 3 as needed

Outcomes: Self-reported pain score (SRPS), PROMIS Pain Interference, patient satisfaction, opioid breakthrough use

Key Findings

  • Pain scores improved significantly (p=0.04)
  • Pain interference scores improved (p=0.001)
  • Patient satisfaction with pain management increased (p<0.001)
  • No significant change in breakthrough opioid use (p=0.49)
  • Twice-daily VR may be more effective than once-daily dosing

Context & Related Research

  • Tepe et al., 2025: Systematic review confirming VR reduces oncology pain with study heterogeneity (PMID:40797462), affirming analgesic potential
  • Uçgun & Çitak, 2025: RCTs support VR for broader cancer symptom control including pain (PMID:40632238)
  • Dong et al., 2025: Meta-analysis shows VR reduces needle-related procedural pain in cancer (PMID:40563604)
  • Eskici et al., 2025: RCT evidence supports VR decreasing chemo-associated stress and pain (PMID:40179266)
  • Hernandez et al., 2025: Pilot trial shows VR’s feasibility and safety in lung cancer outpatient symptom improvement (PMID:40131484)

Clinical Implications

  • VR is a practical adjunct for outpatient cancer pain offering notable analgesic and satisfaction benefits
  • Consider implementing twice-daily dosing based on pilot findings to optimize analgesic response
  • Further monitoring of opioid use effects is essential due to inconclusive results on breakthrough opioid reduction
Strengths Limitations
Phased VR dosing design elucidates dose-response Small sample size limits power and generalizability
Use of validated measures for pain and satisfaction Short duration (3 weeks), long-term efficacy unclear
High adherence to VR intervention protocol No significant effect on breakthrough opioid use assessed

Future Directions

Large randomized trials are needed to define optimal VR dosing, durability of analgesia, impacts on opioid consumption, and applicability across diverse oncology populations.

Conclusion

Virtual reality outpatient distraction therapy significantly reduces chronic cancer pain, with evidence suggesting twice-daily VR dosing may optimize pain control.

Listen to the Podcast

A short discussion of today’s highlight.

Open the episode in a new tab

© 2025 PACULit